ENDO 2026 Abstract Submission Instructions

General Information
Submitting Your Abstract
After Your Abstract Has Been Submitted

ENDO 2026 will take place June 13 – 16, 2026 in Chicago, Illinois. Abstracts are accepted for poster, Rapid-Fire, and Oral presentations. Please read the following Abstract Submission Instructions before submitting your abstract. If you have any questions not answered here, email [email protected].

Abstracts will not be accepted for this submission period beyond the stated deadline, Thursday, January 15, 2026, at 1:00 PM ET.

General Information

Payment

A non-refundable fee of $99.00 USD is due at the time of abstract submission. (Major credit cards are accepted). 

Membership

Membership is not a requirement to submit an abstract for ENDO; however, Endocrine Society members receive special discounted ENDO registration rates.  Additionally, you must be an Endocrine Society member to be considered for abstract awards. Join Now to get the best rate for ENDO.

Submitting Your Abstract

Submission Steps

You will be prompted to complete the following tasks when submitting an abstract: 

• Step 1 Abstract title and Author Agreement/License to Publish
• Step 2: Presentation Preference
• Step 3: Abstract Body and Topic/Subtopic
• Step 4: Abstract Authors
• Step 5: Author Disclosures
• Step 6: Abstract Submission Questions
• Step 7: Abstract Awards
• Step 8: Payment of Nonrefundable $99USD Abstract Handling Fee

If you are unable to finish your abstract submission in one sitting, you must at least submit the abstract type, title, and presentation preference to have your submission saved. Once saved, you can return to the submission time any time before the stated deadline to complete your submission. 

All abstracts must be completed and submitted by the abstract submission deadline. If you do not complete the submission prior to the deadline, your abstract will not be considered for presentation at ENDO 2026.

Step 1: Abstract Title and Author Agreement and License to Publish

Abstract Title

Abstract titles should be short and specific, and entered in title case (the first letter of each word is capitalized, except for certain small words, such as articles, conjunctions, and prepositions).  For assistance with putting your abstract title in title case, visit www.capitalizemytitle.com. 

Example:

This Is a Properly Formatted Title

Author Agreement and License to Publish
Before completing your ENDO abstract submission, you must submit an appropriate response to the Author Agreement and License to Publish. The agreement that you sign depends on whether you are (a) submitting on your own behalf in your own personal capacity, (b) submitting in the scope of your employment with a third-party, private employer, or (c) submitting in the scope of your employment as a federal government employee.  Select the capacity in which the submitting author is submitting the abstract to access and sign the correct agreement.

Step 2: Presentation Preference

You may select your abstract to be considered for an Oral Presentation, Rapid-Fire Poster Presentation, or a Traditional Poster Presentation.  If you don’t have a preferred mode of presentation for your abstract, select “No Preference”.  

Note: Authors of accepted abstracts will receive further information and technical guidelines on how to prepare for their oral, rapid-fire, or poster presentation.

Oral Presentations

The highest-ranked abstracts will be selected for Oral Presentations, which will take place June 13–15, 2026, during ENDO.

Presenting authors will deliver a 10-minute presentation using slides to summarize their research, followed by a 3–5 minute question-and-answer session with the audience. This format provides an opportunity to share key findings with a larger audience and engage in direct discussion with peers and experts.

Note: Abstracts not selected for an Oral Presentation will automatically be considered for Rapid-Fire or Poster Presentation. Abstracts chosen for Oral Presentation will not present a physical poster.

Rapid-Fire Poster Presentations

Rapid-Fire Poster Presentations will take place June 13–15, 2026, during ENDO. These sessions are designed as brief previews of selected poster presentations.

Presenting authors selected for a Rapid-Fire session will present both a Rapid-Fire presentation and a poster. The Rapid-Fire presentation will be scheduled before the corresponding poster session.

Each Rapid-Fire presentation consists of a 5-minute talk with no more than five slides, highlighting the key findings and significance of the work. Audience questions will not be taken during the Rapid

Fire presentation and should be addressed during the presenter’s poster session.

Select this option if you prefer not to be considered for an Oral Presentation but would like to share a concise synopsis of your work in the Rapid-Fire format.

Poster Presentations

Poster Presentations will take place June 13–15, 2026, during ENDO. Presenting authors will have the opportunity to display a traditional printed poster on the expansive poster floor.

Each presenter will be assigned one day to display their poster and is required to be present during a 90-minute Poster Networking Session to discuss their research and engage with attendees.
High-scoring posters will be invited to participate in the Poster Highlight Tour, offering additional visibility for outstanding work.

Select this option if you do not wish to be considered for an Oral or Rapid-Fire Presentation and would like to present your research in the interactive environment of the Poster Hall.

No Preference

Select this option if you do not have a preference for how your abstract is presented and wish to leave the decision up to abstract sessioners.

Step 3: Abstract Body and Topic/Subtopic

Abstract Topic/Subtopic: Select an appropriate topic and subtopic for your abstract.  Select the option that best fits your submission.  This selection helps to determine your abstract’s reviewers.  If accepted, your selected topic and subtopic will help determine your presentation assignment amongst all other abstract submissions at ENDO.

Abstract Character Limit: Maximum of 2,500 characters, including punctuation (not spaces), for the text of your abstract body. Figures, tables, graphs will not be accepted. All abstracts must be in English. References are allowed but not required and should be included in the body of your abstract. If you include references, they will count toward the 2,500-character limit.

Abstract Body: Type the text of your abstract into the appropriate text box or copy and paste it from an existing document. 

All submissions must contain results.

PLEASE NOTE: To preserve the blind peer review process, do not include any identifying information (institution or author names) in your abstract. All co-authors/primary investigators, their institutional affiliations, and any disclosures must be entered in steps 2 and 3 for abstract authors and disclosures. 

Graphics (e.g., figures and tables) are not accepted in the body of your abstract.

IMPORTANT: Please carefully review your abstract and author information before finalizing your submission. Submitting authors may edit their abstract by returning to the abstract submission site at any time prior to the submission deadline. No edits can be made once the submission site closes. Accepted abstracts will be published online in the ENDO program, in the ENDO mobile app, and in the Journal of the Endocrine Society (JES). Authors will not have an opportunity to review or approve proofs of their abstract before it appears online and in JES, and corrections after publication in JES are not possible.

Step 4: Abstract Authors

Edits to authors will not be accepted after the abstract submission deadline. Please review this information carefully to ensure you have included all authors. 

NOTE: There can be only one Presenting Author in your submission. Additionally, only one author will be allowed to present the abstract at ENDO.

Use the Author Look-up tool first to add authors to your submission.  The Author Look-up tool ensures that authors are attributed correctly when added to multiple abstracts. If you cannot find your author(s) using the look-up, you may enter your authors manually. Once your co-authors have been added, you will be prompted to complete their profile information. Up to 30 authors are allowed on each abstract. 

Author Types: 

• Submitting Author: Author completing the abstract submission form online. 
• Presenting Author: The author who will present the abstract at ENDO 2026, and who is required to register for the meeting.  This is the author who will receive communications about the acceptance status of the abstract and its presentation status.
• Senior Author/Principal Investigator: Author who leads the research/investigation described in the abstract.
• Co-Author: Author who contributed to the work described in the abstract that is not described by other author types.

NEW for 2026: Abstract submitters can invite their co-authors to complete their own author information on the abstract.  Once prompted, co-authors will receive an email alert to complete their author profile.  The submitting author will be alerted once the co-author has completed their information.  

Step 5: Author Disclosures and COI Resolution

In accordance with requirements of the Accreditation Council for Continuing Medical Education (ACCME), the Endocrine Society requires all individuals who are in a position to control the content of a CME activity to disclose all financial relationships with any commercial interest that produces, markets, resells, or distributes healthcare goods or services consumed by or used on patients.

Financial relationships are defined as remuneration paid to you in any amount that has occurred within the last 24 months when these two conditions apply:

• You have a financial relationship with a commercial interest.
• You have the opportunity to affect CME content related to the products or services of that commercial interest.

If a potential conflict of interest exists as a result of a financial relationship, this will need to be resolved prior to the activity. All financial relationships must be disclosed to learners at the beginning of the CME activity. If no financial relationships exist, learners must be informed of that as well.

Conflict of Interest

If you listed a conflict of interest for your abstract presentation when you completed your disclosures, and a potential conflict exists as a result of a financial relationship, this will need to be resolved prior to the activity. Please complete this step to assist with resolving any potential conflict of interest so that the Endocrine Society may provide CME for your presentation, if applicable.

NEW for ENDO 2026: Abstract submitters can invite their co-authors to complete their own disclosures and conflict of interest resolution.  Once prompted, co-authors will receive an email alert to submit their information.  The submitting author will be alerted once the co-author has completed their information.  

Step 6: Submission Questions

• Question 1: Religious Conflicts – indicate if any conflicts exist that would prevent you from presenting on certain days.
• Question 2: Abstract Publication – Indicate if you agree to have your abstract included in the Journal of the Endocrine Society after the meeting. 
• Question 3: Embargo and Advance Access Restriction – indicate if you do not want your full abstract posted online until the date of your presentation. NOTE: If you select “No”, the text of your abstract will not appear in the ENDO Mobile App or Program Planner until the date of presentation. Only the title and author block for your abstract will be available in the ENDO mobile app and web site prior to the meeting.
• Question 4: Quality Improvement and Patient Safety – Indicate if the abstract covers quality improvement and patient safety.
• Question 5: Health Care Disparities – Indicate if the abstract discusses issues related to health care disparities.
• Question 6: Rising Star Power Talks – Allows the submitter to opt-in to being considered for a Rising Star Power Talk session.  Rising Star Power Talks are a competitive style of oral presentations at ENDO that focuses on the big-picture relevance of fundamental endocrine research. The sessions will feature basic and clinical science trainees and early career members with top-scoring abstracts. Speakers will be expected to emphasize and clearly communicate the significance of their research to a general audience. Each presentation will be three minutes followed by a two-minute Q&A, and presenters will only be allowed one PowerPoint slide. Audience members will vote on their favorite presentation along with the judges, and the winners will receive complimentary registration to ENDO 2027.
• Question 7: Newsworthy Abstracts – Indicate if the submission should be considered as a newsworthy abstract. Abstracts featuring major new findings, clinical breakthroughs, or research with broad public impact may be selected as newsworthy. These abstracts could be highlighted in Endocrine Society press releases. Authors will be notified in advance if their work is chosen for media coverage.

Step 7: Awards (Optional) 

The Endocrine Society provides awards to recognize outstanding work in endocrinology. These recognition awards are given to outstanding abstracts submitted by in-training fellows and new faculty who have been accepted to present their research during the annual meeting (ENDO). Visit endocrine.org/awards for award criteria and more information.  Winners are selected based on award criteria and abstract score.

Standard Award Requirements:

• You MUST be the first and presenting author on the abstract submission.
• You MUST be currently in-training (Graduate Student, Medical School Student, Clinical or Post-Doctoral Fellow) or early career junior faculty (within 3 years of completing your fellowship and/or 1st - 2nd year of appointment)
• You MUST be an Endocrine Society member to be considered for an abstract-based award. Learn more about the benefits of membership, including discounted ENDO registration, at endocrine.org/membership.

Step 8: Payment

The ENDO 2026 abstract fee is $99 (USD) per abstract. Abstract fees are non-refundable. Visa, Master Card, and American Express are accepted.

Note: Paying the abstract submission fee does not register you for ENDO 2026. All abstract presenters must register to attend ENDO 2026. Please visit  endocrine.org/endo2026 for registration information.

If you are having difficulty finalizing your payment, contact technical support. 

• Email: [email protected]
• Phone: (410) 638-9239
• Online Technical Support Form: You may also submit a support ticket using the Technical Support form at the top of the submission site. 

Review your Submission

Carefully review your abstract and author information before the abstract submission site closes. No edits can be made once the submission site closes; however, submitters are welcome to make updates to their submission any time prior to the deadline. Accepted abstracts will be published online in the ENDO program, in the ENDO mobile app, and in the Journal of the Endocrine Society (JES). Authors will not have an opportunity to review or approve proofs of their abstract before it appears online and in JES, and corrections after publication in JES are not possible. 

The submitting author will receive an email confirming your submission. All abstracts must be completed and submitted by the abstract submission deadline.  If you do not complete the submission prior to the deadline, your abstract will not be reviewed.

After Your Abstract Has Been Submitted

Complete Edits before Submission Deadline

Submitting (contact) authors may return to the abstract submission site any time prior to the submission deadline to edit their abstract. NO REVISIONS to the abstract or the list of authors will be allowed once the site closes on the deadline date. 

Abstract Withdrawal

To withdraw your submission: 

• Return to the submission site.
• Log in using the credentials of the abstract’s submitting author. 
• Select the abstract that you wish to withdraw and change the Abstract Status to “Withdrawn”.

Abstracts accepted for presentation must be withdrawn before: 

• Friday, February 20, 2026, to avoid publication in any meeting materials, including the ENDO website and mobile app. 
• Friday, May 22, 2026, to ensure removal prior to ENDO 2026. 

The $99USD abstract handling fee is not refundable.

Notice of Abstract Acceptance 

Abstract notifications will be emailed to presenting authors only in March 2026.

Abstract Sessioning

Authors of accepted abstracts will receive presentation details, information, and technical guidelines on how to prepare for their oral, rapid-fire, or poster presentation. Presenting authors will not be allowed to reschedule their presentation except for religious reasons (as identified in Step 7 of the submission process).

Abstract Publication

All accepted abstracts from registered presenters will be published on the meeting website and in a supplemental issue of the Open Access and assigned a DOI.